Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

3630 - Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)

Date

10 Sep 2017

Session

Genitourinary tumours, prostate

Presenters

Nicholas James

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

N.D. James1, J. de Bono2, M.R. Spears3, N.W. Clarke4, M.D. Mason5, D. Dearnaley2, A.W..S. Ritchie6, M. Russell7, C. Gilson8, R. Jones7, S. Gillessen9, D. Matheson3, S. Aung10, A. Birtle11, S. Chowdhury12, J. Gale13, Z. Malik14, J. O'Sullivan15, M.K. Parmar16, M.R. Sydes17

Author affiliations

  • 1 Oncology, Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
  • 2 Oncology, Institute of Cancer Research Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 3 Clinical Trials Unit, MRC, London - WCB NH/GB
  • 4 Oncology, Royal Salford NHS Foundation Trust, Salford - M HD/GB
  • 5 School Of Medicine, Cardiff University, Cardiff - Cardiff/GB
  • 6 Urology, Gloucestershire Royal Hospital, London/GB
  • 7 Oncology, University of Glasgow, Glasgow/GB
  • 8 Mrc Clinical Trials Unit, University College London, London/GB
  • 9 Medical Oncology, Kantonsspital, Switzerland/CH
  • 10 Oncology, Royal Devon & Exeter Hospital NHS Foundation Trust, Devon/GB
  • 11 Medical Oncology, Royal Preston Hospital, Preston/GB
  • 12 Medical Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 13 Oncology, Queen Alexandra Hospital, Portsmouth/GB
  • 14 Oncology, Clatterbridge Oncology Centre, Clatterbridge/GB
  • 15 Oncology, Northern Ireland Cancer and Queens University Belfast, Belfast/GB
  • 16 Mrc Clinical Trials Unit, MRC Clinical Trials Unit at UCL, WC2B 6NH - London/GB
  • 17 Mrc Clinical Trials Unit, Institute of Clinical Trials and Methodology-UCL, WC2B6NH - London/GB
More

Resources

Abstract 3630

Background

Abiraterone acetate and prednisolone (AAP) improved survival in men with castration-refractory PCa; we assessed it earlier in the disease. STAMPEDE is a randomised controlled trial using a multi-arm multi-stage platform design, recruiting pts starting long-term ADT with high-risk locally advanced or metastatic PCa. The overall survival advantage of HR = 0.63 was dominated by deaths in M1 pts. We focus on outcomes in the “AAP comparison” pt subgroup with M0 disease at randomisation.

Methods

Standard-of-care (SOC) was ADT for 2+yr; radiotherapy (RT) was mandated for N0M0 disease (unless contraindicated) & encouraged for N+M0. Stratified randomisation allocated pts 1:1 to SOC or SOC+abiraterone acetate 1000mg + prednisolone 5mg daily (SOC+AAP). AAP continued to PSA, radiological & clinical progression, capped at 2 years in pts having radical RT. The definitive primary outcome measure (OM) was death from any cause; Failure-Free Survival (FFS) was the intermediate primary OM. Secondary OMs included Metastasis-Free Survival (MFS). Analyses used Cox proportional hazards, adjusted for stratification factors.

Results

915 M0 pts were randomised to SOC or SOC+AAP from Nov 2011 to Jan 2014: median age 67 yr (IQR 44-84); 81% WHO PS 1; 42% N+M0; 82% planned to receive SOC RT; median follow-up 38m. N0M0 pts not planned for RT (previously treated or contraindication) are not excluded from subgroup estimates. FFS was improved in SOC+AAP in N0M0: HR = 0.14 (95%CI 0.07-0.30) with 3yr FFS 80% SOC vs 98% SOC+AAP. In N+M0, FFS was improved on SOC+AAP HR = 0.26 (95%CI 0.17-0.40), translating into an effect on survival consistent with the overall trial estimate, HR = 0.67 (95%CI 0.39- 1.17). Estimates of MFS are favourable for SOC+AAP within both subgroups; N0M0 HR=0.62 (95%CI CI 0.33-1.14), N+M0 HR=0.47 (95%CI 0.29-0.78). Survival estimates in N0M0 pts are immature, with only 26 deaths.

Conclusions

Early clinical outcomes for all M0 pts who had AAP are excellent, particularly in N0M0 pts also planned for RT. The models from the ICECaP project suggest that MFS improvements of this magnitude in M0 pts should translate into a survival advantage.

Clinical trial identification

NCT00268476

Legal entity responsible for the study

UK Medical Research Council

Funding

MRC, CRUK, Janssen; Astellas, Clovis Oncology, Novartis, Pfizer, Sanofi Aventis

Disclosure

N. James: Grants, personal fees and non-financial support from Janssen, Astellas, Sanofi, Novartis during the conduct of the study; grants and non-financial support from Clovis Oncology, Pfizer. J. de Bono: Other from AstraZeneca, Glaxosmithkline, Pfizer, Taiho, Daiichi, Novartis, Genmab, Merck Serano, Merck, Genentech/Roche. Has a patent null pending. N.W. Clarke: Personal fees from Janssen Pharmaceuticals, during the conduct of the study. Personal fees from Janssen Pharmaceuticals, outside the submitted work. M.D. Mason: Personal fees and other from Sanofi, personal fees from Bayer, other from Janssen, outside the submitted work. D. Dearnaley: UK National Institute for Health Research Clinical Research Network, Janssen Pharma, Sandoz Pharmaceuticals, Cadence Research, Janssen-Cilag, ISSECAM, other from Clovis. Royalties from a patent GB9305269 – 17. M. Russell: Janssen-Cilag, outside the submitted work. C. Gilson: Grants from Clovis Oncology, outside the submitted work. R. Jones: Personal fees and non-financial support from Janssen and Astellas, outside the submitted work. S. Gillessen: Bayer, CureVac, Janssen Cilag, Dendreon Corp, Astellas, Millennium Pharmaceuticals, Orion, Sanofi, MaxiVax SA, AAA, Bristol-Myers Squibb, Ferring, Roche, Innocrin Pharmaceuticals, Nektar Therapeutics, ProteoMedix. A. Birtle: Advisory boards to disclose with Astellas, Janssen, Sanofi and outside of relevant work with AstraZeneca and Bayer. S. Chowdhury: Personal fees from Janssen Paharmaceutical, outside the submitted work. Z. Malik: Consultancy and advisory boards Janssen, Sanofi and Astellas Sponsorship to attend medical conferences Astellas, Bayer and Janssen. J. O\'Sullivan: Personal fees from Janssen, outside the submitted work. M.K. Parmar: Grants and non-financial support from Janssen, Astellas, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis, outside the submitted work. M.R. Sydes: Grants and non-financial support from Janssen, Astellas, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.